Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cyanotech Corporation (CYAN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.0300-0.0300 (-0.98%)
At close: 02:35PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close3.0600
Open3.1000
Bid3.0700 x 1400
Ask3.3900 x 900
Day's Range3.0300 - 3.1000
52 Week Range2.5600 - 3.9500
Volume2,381
Avg. Volume16,090
Market Cap18.797M
Beta (5Y Monthly)0.42
PE Ratio (TTM)8.66
EPS (TTM)0.3500
Earnings DateAug 09, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-5% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CYAN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cyanotech Corporation
    Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
Advertisement
Advertisement